Biopharmaceutical company AstraZeneca (LSE: AZN) (STO: AZN) (Nasdaq: AZN) announced on Monday that it has successfully finalised its acquisition of Amolyt Pharma, a clinical-stage biotechnology firm specialising in novel treatments for rare endocrine diseases. This acquisition strengthens Alexion, AstraZeneca Rare Disease's late-stage pipeline and expands its bone metabolism portfolio with eneboparatide (AZP-3601), a Phase III therapeutic peptide targeting hypoparathyroidism, a condition marked by disrupted calcium and phosphate regulation.

The deal, valued at up to USD1.05bn on a cash and debt-free basis, includes an USD800m upfront payment at closing and a contingent USD250m based on achieving specified regulatory milestones. AstraZeneca anticipates integrating Amolyt Pharma's talent and pipeline to bolster its presence in rare endocrinology.

Eneboparatide (AZP-3601) is designed to bind tightly to the parathyroid hormone receptor, aiming to regulate serum calcium levels, reduce urine calcium excretion and potentially mitigate kidney function decline and bone integrity issues in hypoparathyroidism patients.

AstraZeneca, headquartered in Cambridge, UK, is focussed on Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism and Respiratory & Immunology. Operating in over 125 countries, the company's medicines are vital to millions of patients worldwide.

biopharmaceutical leader